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Abstract
Dengue virus (DENV) is the etiological agent of dengue fever. Severe dengue could be fatal and there is currently
no effective antiviral agent or vaccine. The only licensed vaccine, Dengvaxia, has low efficacy against serotypes 1
and 2. Cellular miRNAs are post-transcriptional regulators that could play a role in direct regulation of viral genes.
Host miRNA expressions could either promote or repress viral replications. Induction of some cellular miRNAs could
help the virus to evade the host immune response by suppressing the IFN-α/β signaling pathway while others
could upregulate IFN-α/β production and inhibit the viral infection. Understanding miRNA expressions and
functions during dengue infections would provide insights into the development of miRNA-based therapeutics
which could be strategized to act either as miRNA antagonists or miRNA mimics. The known mechanisms of how
miRNAs impact DENV replication are diverse. They could suppress DENV multiplication by directly binding to the
viral genome, resulting in translational repression. Other miRNA actions include modulation of host factors. In
addition, miRNAs that could modulate immunopathogenesis are discussed. Major hurdles lie in the development of
chemical modifications and delivery systems for in vivo delivery. Nevertheless, advancement in miRNA formulations
and delivery systems hold great promise for the therapeutic potential of miRNA-based therapy, as supported by
Miravirsen for treatment of Hepatitis C infection which has successfully completed phase II clinical trial.
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Introduction
MicroRNAs (miRNAs) are a class of small non-coding
RNAs (18–25 nucleotides) which function as key post-
transcriptional regulators of gene expression. By binding
to the complementary 3′-untranslated regions (3’UTR) of
specific messenger RNAs (mRNAs), miRNAs prevent
translational events, either through mRNA degradation or
translational repression [1]. At present, more than 2000
human miRNAs are known, implying a powerful regula-
tory role of miRNAs in diverse aspects of development
and physiology [2]. miRNA can be considered as master
regulators as they regulate the expressions of about 60% of
the protein-coding genes in the human genome. A single
mRNA can be targeted by different miRNAs or one
miRNA can bind to multiple mRNAs [3]. It is therefore
not surprising to observe an aberrant expression profile of
miRNAs in various human diseases [4].
Viruses are obligate intracellular parasites that rely highly
on host metabolic processes to create specific microenvi-
ronments required for viral replication and infectivity. In
the event of a viral infection, miRNAs are actively involved
in the interplay between viruses and hosts, from viral at-
tachment to disease progression. The presence of micro-
RNA Response Elements (MREs) which are generally
located in the 5’UTR and 3’UTR of the viral genome, has
supported the underlying mechanism of miRNA-mediated
antiviral activities [5, 6]. One of the earlier evidence refers
to miR-32 which has been reported to effectively restrict
primate foamy virus type I replication by targeting the viral
genome [7]. Nevertheless, there was also evidence where
miRNA directly binds to the viral genome, resulting in
enhanced viral genome stability and translation. This
unconventional miRNA-mediated effect has been well ex-
emplified by miR-122, a liver-specific miRNA which con-
tributes to Hepatitis C virus (HCV) liver tropism [5]. miR-
122 stabilizes the HCV genome by forming an oligomeric
complex with the HCV genome. It was reported to bind to
two closely target sites (S1 and S2) in the 5’UTR of HCV
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genome, thereby protecting the viral genome from nucleo-
lytic degradation [8, 9]. On the basis where sequestration of
miR-122 in liver cell lines strongly downregulated HCV
replication in liver cells, the miR-122 antagonist Miravirsen
has been shown to be an antiviral agent against HCV
infection.
Similar to other viruses, miRNA-related research of
Dengue virus (DENV) has been growing in recent years.
DENV is a mosquito-transmitted, positive sense virus
which belongs to the Flavivirus genus of the Flaviviridae
family. There are four distinct, but closely related sero-
types of the dengue virus, namely DENV-1, DENV-2,
DENV-3 and DENV-4. Over the last few decades, dengue
has become one of the major public health challenges in
the world, especially in tropical and subtropical countries.
The World Health Organization (WHO, 2017) reported
that the incidence of dengue has increased 30-fold in the
recent 50 years [10]. Bhatt and associates estimated that
390 million dengue infections occurred annually, of which
96 million cases were manifested clinically [11]. Another
study estimated that the risk of dengue infection will rise
and could infect 3.9 billion people in 128 countries across
the world [12]. As a disease which is endemic in over 100
countries, dengue has put almost half of the world’s popu-
lation at risk. In this review, we describe the involvement
of miRNAs in the host-pathogen interactions of DENV.
Interestingly, miRNAs could act as an antiviral regulator
or a proviral factor that favors DENV multiplication.
Dengue virus: host-pathogen interactions
DENV entry and replication
DENV has a 10.7-kb capped RNA with 5′ and 3′ UTRs
flanking a single open reading frame that encodes three
structural proteins (C, capsid; prM/M, pre-membrane/
membrane; E, envelope) and seven non-structural proteins
(NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) [13]. Dengue
infection starts with a bite by the DENV-infected Aedes
mosquitoes, Aedes aegypti or Aedes albopictus. Upon
DENV inoculation into the skin by a mosquito bite, the
virus is taken up by the tissue-resident dendritic cells or the
macrophages via clathrin-dependent receptor-mediated
endocytosis. DENV attaches to dendritic cell-specific intra-
cellular adhesion molecule-3-grabbing non-integrin (DC-
SIGN) on dendritic cells [14]. The mannose receptor on
macrophages binds to DENV surface proteins via the lectin
activity of the carbohydrate-binding domains of the DENV
envelope protein [15].
Host innate immune response against DENV infection
Upon DENV entry into cells, the viral RNA is uncoated
and following replication, the dsRNA can be recognized
by the host pattern recognition receptors (PRRs). The
PRRs include the Toll-like receptors (TLR3, TLR7 and
TLR8) and the host RNA sensors comprising the
retinoic acid-inducible gene I protein (RIG-1)-like recep-
tors and melanoma differentiation-associated protein 5
(MDA5) [16]. The cytoplasmic helicases, RIG-1 and
MDA5, could detect the presence of the virus through
binding to viral RNA. Upon viral recognition, there is an
activation of interferon regulatory factors and the NF-
κB. These torrent of immunological signals could then
trigger the induction of the type I interferons (mainly
IFN-α and IFN-β), leading to robust production of
inflammatory cytokines including IL-8. Subsequently,
dendritic cells are activated with the establishment of an
antiviral response [16, 17].
Toll-like receptor 3 (TLR3) was shown to have a pivotal
role in the recognition and restriction of DENV replication
in several cellular lineages [16, 18, 19]. An in vitro study
demonstrated the synergism of RIG-I, MDA5 and TLR3 in
the induction of IFN-β production that eventually
suppressed DENV replication [18]. Binding of RIG-1 and
MDA5 to viral RNA activate the phosphorylation of inter-
feron regulatory factor 3 (IRF3), which in turn initiated IFN
production [17, 18]. Although type I IFN suppression has
been well recognized as an apparent pathogenic strategy of
DENV to evade the host immune response, evidence has
shown that there was a relatively mild activation of IFN-α
and IFN-β during DENV infection [20–22].
To date, a number of DENV proteins have been identi-
fied as the inhibitors of IFN-α/β signaling pathway by
interfering with different targets along the pathway. DENV
NS2A, NS4A and NS4B have been shown to work in con-
cert to block the phosphorylation of the signal transducer
and activator of transcription 1 (STAT1) and nuclear
translocation [23]. Another DENV protein, NS5, has been
shown to bind directly to signal transducer and activator
of transcription 2 (STAT2) protein, which subsequently
directed it towards proteasomal degradation [24]. As a re-
sult, the formation of STAT1/STAT2 heterodimer and its
subsequent transcriptional induction of interferon stimu-
lated genes (ISGs) was prevented. In addition, recent stud-
ies have discovered a novel immune evasion strategy of
DENV. The viral protease NS2B3 enzymatically cleaved
the human mediator of interferon regulatory factor 3
(IRF3) activation (MITA), also known as the stimulator of
interferon genes (STING), which downregulated IFN pro-
duction [25, 26]. The other study discovered that DENV
NS4A was able to bind to the mitochondrial antiviral sig-
naling adaptor (MAVS), thereby preventing it from associ-
ating with RIG-1 and abrogating IFN induction [27].
Immunopathogenesis of DENV infection
Dengue fever is a non-fatal disease with symptoms like
high fever, headache, vomiting, pain behind the eyes,
muscle and joint pain as well as a characteristic skin rash.
Unfortunately, a small but significant proportion of den-
gue patients could develop the Dengue Haemorrhagic
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Fever (DHF) and the Dengue Shock Syndrome (DSS)
which are life-threatening. The pathogenesis of severe
dengue has been attributed to immunopathogenesis which
elicited an abrupt “cytokine storm”, leading to vascular
leakage, hypotension and shock [28]. The complexity of
DENV infection is due to immune responses that can ei-
ther be protective or pathogenic. Exposure to any of the
four DENV serotypes during primary infection might ren-
der life-long protection against the same serotype. In-
creased risk of severe dengue is highly associated with
heterologous secondary infection, which is a subsequent
DENV infection with a different serotype. Aggravated clin-
ical manifestations of dengue disease from heterologous
secondary infection might be attributed to cross-reactive
T cells [29] or the “antibody-dependent enhancement”
(ADE) [30]. The dominance of cross-reactivity of anti-
bodies or T-cell responses towards the primary infecting
DENV serotype over the secondary infecting serotype was
addressed in the “original antigenic sin” concept of sec-
ondary DENV infections [29]. The involvement of cross-
reactive T cell responses observed in severe dengue mani-
festations infers the pathogenic role of T cells in DENV
infection [31, 32]. The original antigenic sin proposed that
cross-reactive memory T cells from primary infection
might have a lower avidity against the secondary infecting
serotype, which in turn, could result in suboptimal TCR
triggering and subsequent production of high levels of
TNF-α that contributed to vascular permeability and
plasma leakage [33]. Several studies demonstrated the role
of CD4+ and CD8+ T cells in the resolution of DENV in-
fection, whereby serotype-specific responses of the T cells
were seen in primary infection of DENV in humans [34],
and proliferation of CD4+ T cells responding specifically
the NS3 produced IFN-γ that lysed infected cells [35].
Nevertheless, skewed T-cell responses during secondary
heterologous infection might contribute to the severity of
the immunopathogenesis of DHF and/or DSS. Although
secondary DENV infections are either asymptomatic or
display a mild outcome of the disease, the immune mech-
anisms underlying disease severity in some individuals
during heterologous infections warrant further research.
miRNA biogenesis
The biogenesis of miRNAs in humans involves 4 key en-
zymes- Drosha, Exportin 5, Dicer and Argonaute (Ago)
2 [1, 36]. The process commenced with the transcription
of genes encoding miRNAs in the nucleus by the RNA
polymerase II, producing primary transcripts which are
several kilobases long, namely the pri-miRNAs [37–39].
In the nucleus, the pri-miRNAs are processed into pre-
miRNAs by the nuclear Microprocessor complexes con-
sisting of the Ribonuclease III endonuclease Drosha and
the co-factor protein DiGeorge syndrome chromosomal
region 8 (DGCR8). The pre-miRNAs are approximately
70 nucleotides long hairpin structures [40–42]. They are
subsequently transported by Exportin-5 to the cell cyto-
plasm [43–45] where the Dicer protein enzymatically
cleaves the stem-loop precursor to 22 nucleotides long
double-stranded miRNA duplexes which are incorpo-
rated into the Ago proteins, Ago1 and Ago2, in the
miRNA-induced silencing complexes (miRISC) [46–50].
Following this, the duplexes rapidly unwound, giving rise
to the mature miRNA guide strand and the complemen-
tary passenger strand, known as the miRNA star (miR*).
Whilst the mature miRNA is retained in the miRISC,
the miR* is released and degraded in the cytoplasm [51,
52]. miRNA-incorporated RISC complex is ready to me-
diate post-transcriptional silencing by two different
mechanisms, depending on the complementarity with
target mRNA sequences. A perfect complementarity
match generally leads to mRNA degradation, as a result
of the endonuclease activity by Ago2. On the other
hand, translational inhibition occurs as the outcome of
an imperfect complementary binding of RISC to the tar-
get sequences [53].
miRNA-based therapeutic modalities
In general, there are two miRNA-based therapeutic mo-
dalities: miRNA antagonists and miRNA mimics. The
former approach could be applied to inhibit miRNAs with
undesired functions such as miRNAs which are proviral.
A miRNA antagonist is usually introduced as a chemically
modified miRNA which is known as anti-miR or antago-
miR that could complementarily bind to the mature
miRNA strand. To date, several chemical modifications
have been introduced to antimiR oligonucleotides with
the aim of increasing their binding affinity, stability and
in vivo delivery. The most commonly used chemical mod-
ifications include locked nucleic acid (LNA), a bicyclic
RNA analogue in which the ribose is locked in a C3’-endo
conformation, 2’ribose modifications such as 2-O-methyl
(2-MO), 2-fluoro (2-F), 2-O-methoxyethyl (2-MOE) and
the modification of phosphorothioate (PS) backbone [54].
Among them, LNA was reported to be the one with the
highest affinity towards complementary miRNAs. In fact,
this chemical modification was adopted by Santaris
Pharma A/S and Hoffman-La Roche as the miRNA chem-
istry for the very first miRNA therapeutic and adminis-
tered as antimiR oligonucleotide targeting miR-122 for the
treatment of HCV infection [55].
miRNA mimics are synthetic RNA duplexes which
mimic endogenous miRNAs. They are introduced to re-
plenish or to further enhance the levels of miRNAs
which are crucial to control disease progression. These
miRNA mimics provided a promising proof-of-concept
for miRNA replacement therapy. The tumor suppressor
miR-34 mimic (MRX34) is by far the most clinically ad-
vanced therapeutic mimic. Although the MRX34 phase I
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clinical trial was halted in September 2016 due to five
cases of immune-related events [55], the question of
whether miR-34 mimic could serve as a good strategy
for cancer therapeutic remains elusive. Interestingly,
miR-34 family was also reported to have an antiviral role
by induction of IFN-responsive genes and release of type
I interferon, thereby enhancing the host immune re-
sponse against DENV infection. This preliminary result
highlighted the potential to develop miR-34 mimic as an
anti-DENV therapeutic [56].
Impact of miRNAs on DENV infection
Several studies have implied the important roles of miR-
NAs in viral infections. Mutations in the main catalytic
components of the RNA interference (RNAi) pathway led
to an increase in replication of DENV [57], vesicular sto-
matitis virus (VSV) [58], influenza A virus [59] and human
immunodeficiency virus [60, 61] in mammalian cells. To
date, at least two independent studies have extensively
profiled miRNA expressions in the blood of dengue pa-
tients, which consistently showed a significant number of
miRNAs that were differentially expressed in response to
dengue infection. Tambyah et al. [62] showed a profile of
348 differentially-expressed miRNAs in dengue patients,
of which 12 represented the cohort that was specifically al-
tered upon acute dengue infection. Interestingly, this
study also pinpointed 17 miRNAs that could potentially
be utilized to distinguish mild dengue from severe dengue
with complications. Expressions of miR-24-1-5p, miR-
512-5p and miR-4640-3p were able to distinguish mild
dengue from those displaying liver complications while
miR-383 was significantly upregulated in mild dengue
when compared to those diagnosed with severe dengue
and fluid accumulation. In another study by Ouyang et al.
(2016), miRNA PCR arrays showed differential expres-
sions of 12 downregulated and 41 upregulated miRNAs in
the sera of DENV-1 patients when compared to healthy
controls. Amongst these miRNAs, hsa-miR-21-5p, hsa-
miR-146a-5p, hsa-miR-590-5p, hsa-miR-188-5p, and hsa-
miR-152-3p were identified as promising non-invasive
molecular markers for detecting DENV infection. miR-21-
5p and miR146a-5p were functionally involved in inflam-
mation and cell proliferation, and they were significantly
different from the control groups, indicating their high
sensitivity and specificity as indicators of DENV infection.
In addition, both of the miRNAs correlated with the num-
ber of leukocytes and neutrophils. These findings
suggested that some miRNAs could be employed as diag-
nostic markers for DENV infections [63].
Interestingly, it is apparent that an effective disruption of
the host RNAi machinery is one of the pathogenic strat-
egies of viruses to mitigate the host response. Several
viruses have been reported to produce viral suppressors of
RNAi proteins that could suppress miRNA-mediated
silencing of the host RNAi machinery by interfering with
RISC loading or by inhibiting the slicing activity of the Ago
protein, a component of RISC [64–66]. For DENV, viral
RNAi suppressors that could neutralize the host RNAi re-
sponse were also identified. NS4B was reported to suppress
the host RNAi by interfering with the processing of dicer, a
key miRNA biogenesis protein [57] whilst NS3 was demon-
strated to interfere with the miRNA loading to the Ago1
protein [67].
MicroRNA-like small RNAs have been reported to be
produced by RNA viruses such as DENV, West Nile and
H5N1 influenza viruses [68–70]. Hussain et al. (2014)
showed that the miRNA-like viral small RNA DENV-
vsRNA-5 was able to autoregulate DENV replication by tar-
geting the non-structural DENV protein 1 gene and down-
regulated DENV replication.
miRNAs that directly target viral genome to inhibit DENV
replication
miRNAs generally induce translational repression by
binding to MRE sites of the targeted mRNAs. Consistent
with this mode of action, it is not surprising that most
of the miRNAs identified to date have been reported to
affect DENV replication by targeting the viral genome
sequences. Evidence gathered independently pointed to
the fact that miRNAs complementarily bind to the
5’UTR or 3’UTR of DENV genome and thereby inhibit-
ing DENV replication. The first evidence that a miRNA
could suppress DENV multiplication by directly binding
to the viral genome was represented by miR-548 g-3p
[71]. In the study, Wen et al. (2015) [71] showed that
miR-548 g-3p was able to bind to the Stem Loop A
(SLA) promoter in the 5’UTR, which is a key element to
DENV RNA synthesis and replication, and downregu-
lated replication of DENV-1 (strain Hawaii), DENV-2
(strain New Guinea C), DENV-3 (strain Philippine H87)
and DENV-4 (GZ/ 9809/2012) (Table 1). This inhibitory
effect was proposed to arise from the binding of the
miR-548 g-3p to the SLA which might physically hinder
and thereby, attenuated the interaction between the SLA
promoter and NS5, a DENV protein which contains a C-
terminal RNA-dependent RNA polymerase domain.
Castrillon-Betancur and Urcuqui-Inchima [73] revealed
three miRNA candidates which could potentially inhibit
DENV replication by means of bioinformatics predictions
[72]. They hypothesized that a functional miRNA was con-
served amongst all DENV serotypes and identified miRNA
candidate target sites present at the 3’UTR of all four den-
gue serotypes. As a result, they proposed that miR-133a,
miR-484 and miR-744 could downregulate DENV replica-
tion by targeting the 3’UTR of the DENV RNA genome,
specifically, the 3’stem loop which contains elements that
are involved in genome circularization and viral viability
[72, 73]. Indeed, overexpression of miR-133a, miR-484 and
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miR-744 in Vero cells had experimentally been validated to
show the potencies of these three miRNAs in inhibiting
DENV replication.
In another study, miR-252 was found to be highly in-
duced in a DENV-2 (strain New Guinea C) infection
model of the mosquito C6/36 cell line and was able to
suppress DENV replication by targeting the DENV-2 E
gene [74]. The identification of the E protein as the
miRNA target is interesting as this protein was known to
have an indispensable role for cell attachment and viral
entry [82]. As miR-252 is not present in humans, adminis-
tration of miR-252 mimics to prevent the translation of
the E protein in humans might act as an antiviral thera-
peutic with no or minimal off-target effects. Nonetheless,
experiments are required to confirm the importance of
miR-252 in the context of DENV-2 human infection.
miRNAs that modulate host factors to inhibit or facilitate
DENV replication
As viruses are dependent on the host machinery for rep-
lication and infection, it is of no surprise that a number
of miRNAs have been demonstrated to indirectly regu-
late DENV replication through the modulation of the
host factors or immune response. These indirect effects
included modulation of expression of a cellular tran-
script encoding a host factor required for one or a few
steps in the viral cycle. Modulation of receptor expres-
sion could regulate the entry of the virus, thus affecting
tropism and cofactors vital for replication complexes or
translation that could impair or increase viral replication
as well as viral protein production, respectively. In
addition, miRNAs are also known to enhance or restrict
cell responses to the infection like immune response or
defense mechanisms [83].
For example, the highly expressed let-7c has been
speculated to protect the infected Huh-7 cells from oxi-
dative stress and inflammation response following
DENV infection [75]. Let-7c is one of the miRNAs that
was up-regulated during DENV infection in the hepatic
Huh-7 cells and macrophage-monocytic cell line U937-
DC-SIGN. Let-7c was shown to directly bind to the
Basic Leucine Zipper Transcription Factor-1 (BACH1), a
strong repressor of the anti-inflammatory and anti-
oxidant protein Heme Oxygenase 1 (HO-1), and down-
regulated both DENV-2 (strain New Guinea C) and
DENV-4 (strain V3361–1956) infections. As inferred by
its anti-inflammatory and anti-oxidant role, let-7c is
likely able to protect the host from the viral-induced
Table 1 Examples of miRNAs involved in DENV infection
microRNA Virus-types Host system Effect Target Reference
miR-548 g-3p DENV-1 (strain Hawaii), DENV-2 (strain New
Guinea C), DENV-3 (Philippine H87 Strain)
and DENV-4 (GZ/ 9809/2012)
U937 Antiviral Direct: viral 5′ UTR [71]
miR-133a DENV-1, DENV-2 (strain New Guinea C)
and DENV-4
Vero Antiviral Direct: viral 3′ UTR [72]
miR-484 DENV-1, DENV-2 (strain New Guinea C)
and DENV-4
Vero Antiviral Direct: viral 3′ UTR [73]
miR-744 DENV-1, DENV-2 (strain New Guinea C)
and DENV-4
Vero Antiviral Direct: viral 3′ UTR [73]
miR-252 DENV-2 (strain New Guinea C) C6/36 Antiviral Direct: viral gene E [74]
Let-7c DENV-2 (strain New Guinea C) and DENV4
(strain V3361–1956)
Huh7, U937-DC-
SIGN
Antiviral Indirect: BACH1 [75]
miR-30e* DENV-1 (strain Hawaii), DENV-2 (strain
New Guinea C) and DENV-3 (strain H241)
HeLa, U937
and PBMCs
Antiviral Indirect: IκBα [76]
miR-34 family (miR-34a,
miR-34c, miR-449a and
miR-449b)
DENV-2 (strain New Guinea C) HeLa Antiviral Indirect: Wnt pathway [56]
miR-223 DENV-2 (strain TR1751) EAhy926 cells Antiviral Indirect: STMN1 mRNA [77]
miR-3614-5p DENV-2 (strain 16,681) Primary human
macrophage
Antiviral Indirect: ADAR1 mRNA [78]
miR-146a DENV-2 (strain New Guinea C) Primary human
monocytes and
THPI cells
Proviral Indirect: TRAF6 [79]
miR-21 DENV-2 (strain 16,681) HepG2 Proviral Direct: NS1 sequence [80]
mir-150 DENV-2 (strain New Guinea C) PBMCs from
DHF patients
Biomarker for
severe disease
Downregulated SOCS1 resulting
in lower IFN-γ production
[81]
Abbreviations: DENV Dengue virus, UTR Untranslated region, BACH1 Basic leucine zipper transcription factor 1, STMN1 Stathmin 1, ADAR1 Adenosine deaminase
acting on RNA 1, NS1 Non-structural protein 1, SOCS1 Suppressor of cytokine signaling, IFN Interferon, TRAF6 Tumor necrosis factor receptor (TNFR)-associated
factor 6
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excessive production of reactive oxygen species and in-
flammatory response, which is detrimental to the host
[84–88]. Furthermore, another study further supported
the antiviral role of HO-1 against DENV [89]. HO-1 in-
duction was demonstrated to reduce DENV replication
in Huh-7 cells and to delay DENV-2 induced disease
and lethality in suckling mice. The HO-1-mediated anti-
viral effect is likely contributed by the restoration of
antiviral IFN response together with the inhibition of
DENV protease activity by biliverdin, a by-product of
HO-1-catalyzed degradation of heme.
Zhu et al. (2014) demonstrated that the highly expressed
miR-30e* during dengue infection suppressed DENV rep-
lication by enhancing the host antiviral immune response
[76]. When unstimulated, NF-κB was retained in the cyto-
plasm by IκBα, a negative regulator which de-repressed
the translocation of NF-κB into the nucleus upon its deg-
radation [90]. During DENV infection, miR-30e* was
shown to exert the antiviral effect by directly targeting the
3’UTR of IκBα, resulting in the degradation of IκBα. This
led to the subsequent activation of NF-κB pathway, thus
promoting the expression of IFN-β and the downstream
ISGs such as OAS1, MxA and IFITM1, as demonstrated
in both U937 monocytic and HeLa cells [76]. Similar in-
nate modulating role by the miR-34 family (miR-34a,
miR-34c, miR-449a and miR-449b) was also reported in
response to infections caused by a number of flaviviruses,
including DENV [56]. A reduction in DENV-2 (strain
New Guinea C) replication was observed upon increased
expression of the miR-34 family members where the anti-
viral effect was proposed to be due to the suppression of
the Wnt signaling. Wnt signaling is known to repress
glycogen synthase kinase 3 beta (GSK3b) phosphorylation
which positively regulated the IFN signaling pathway. As a
result, miR-34 family increased the expression of type I
IFN and ISGs through suppression of Wnt signaling [56].
Hence, both miR-30e* and miR-34 family of miRNAs
could be considered as positive regulators of the antiviral
immune response of cells upon DENV infections. The
ability of both miRNAs to upregulate the expression of
type I IFN production indicated their therapeutic poten-
tials in suppressing DENV infections in vivo.
Apart from modulating the host immune response, a
study by Wu et al. (2014) provided evidence to link the
antiviral role of miRNA to perturbations of other host fac-
tors. For example, miR-223 was reported to be capable of
inhibiting DENV-2 (strain TR1751) replication and its anti-
viral effect was likely associated with dampened expression
of the microtubule-destabilizing protein, stathmin 1
(STMN1), a key microtubule regulatory protein that con-
trols microtubule dynamics [77]. The exact mechanism of
how STMN1 affected DENV-2 replication remains unclear.
Nevertheless, insights from a previous study had demon-
strated that an intact microtubule network involved in
sequestration of STMN1 was essential for HCV to establish
an infection. As such, it is highly probable that STMN1 is
playing a similar role in establishing controlled microtubule
dynamics in the context of DENV infection [91]. Addition-
ally, miR-133a was hypothesized to suppress DENV multi-
plication by direct targeting of the polypyrimidine tract-
binding protein (PTB). PTB is a host cellular protein that
has been proposed to act as RNA helicase by binding to the
conserved sequence 1 and long stem-loop structures of the
3’UTR of DENV [92, 93].
Diosa-Toro (2017) identified a miRNA with moderate
but significant antiviral property against DENV. In the
study, miRNA-3614-5p was found to be upregulated in
DENV-negative cells and its overexpression reduced
DENV infectivity. This miRNA-3614-5p was found not
only to reduce DENV but also West Nile virus infectiv-
ity. Adenosine deaminase acting on RNA 1 (ADAR1)
was analyzed as one of the targets of miR-3614-5p and
was demonstrated to stimulate DENV infectivity at early
time points post-infection. Taken together, the study ex-
tended the knowledge of the contribution of human
miRNAs in building the network of interactions between
DENV and its human host cells [78].
In contrast, miRNAs could also modulate the host fac-
tors or immune response in a way that favour viral repli-
cation. Several miRNAs have been reported to positively
modulate viral replications, such as miR-1 in Hepatitis B
and miR-122 in HCV infections. Nevertheless, miR-146a
was the only miRNA identified to date that had a pro-
viral effect in response to dengue infection [79]. Interest-
ingly, this miRNA was highly expressed in the primary
and transformed monocytes (THP-1 cells), the major
target cells for the initial attachment of DENV, implying
a crucial role of miR-146a in establishing an infection.
Further study into the molecular mechanism proposed
that miR-146a enhanced DENV-2 (strain New Guinea
C) replication by dampening the host IFN-β production
which was mediated through targeting tumor necrosis
factor receptor (TNFR)-associated factor 6 (TRAF6).
Ideally, a regimen that could repress the level of miR-
146a might reverse the virus-mediated immune re-
sponse. Administration of the LNA-antagomir-146a was
reported to significantly decrease Enterovirus A71 (EV-
A71) replication in mice [94]. Pu et al. (2017) demon-
strated overexpression of miR-146a significantly blocked
DENV-2 (strain New Guinea C) by inducing autophagy
and LNA-mediated inhibition of miR-146a was able to
counteract the effects [95]. In light of this finding, miR-
146a antagonist might be a suitable candidate to restore
the host IFN activity against DENV. However, one im-
portant concern is the potential off-target effects associ-
ated with a skewed transcription of type I IFN. While
type I IFN is essential in inhibiting viral replication
through the induction of ISGs, inappropriate or
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excessive type I response could lead to detrimental ef-
fects. These damaging effects might be through direct
tissue damage by apoptosis or immunopathology due to
excessive inflammation [96]. This is relevant to dengue
infection as excessive inflammation is the hallmark of
fatal severe dengue. In another study, Kanokudom et al.
(2017) found that the expression of miR-21 was signifi-
cantly increased upon DENV-2 (strain 16,681) infection
which promoted DENV-2 replication [80]. This result
was similar to the effect of miR-146a [79]. A significant
reduction in DENV-2 production was observed upon
treatment with an anti-miR-21 (AMO-21) prior to
DENV infection in HepG2 cells, indicating that miR-21
played a crucial role in DENV-2 replication. However,
the mechanism of how miR-21 induced DENV replica-
tion is still unclear and miR-21 might directly target
NS1 protein sequence of DENV-2 genome [97].
miRNAs identified to date are mostly associated with
DENV replication, either via direct targeting of the viral
genome or through modulation of the host mediators
which are essential for DENV multiplication. Although
some studies have shown that the DENV viral load had
a positive correlation with dengue severity [98–100],
other studies have proposed that the dengue viral load
was not significantly associated with DHF and dengue
fatality [75, 82, 84]. Severity in dengue disease is strongly
associated with a systemic inflammatory response syn-
drome, commonly known as the “cytokine storm”. It is a
phenomenon which occurs when there is an imbalance
between the pro-inflammatory and anti-inflammatory
mediators. However, whether the immune responses are
skewed towards either type 1 or type 2 is paradoxical
[101]. Pro-inflammatory cytokines such as TNF-α are
believed to activate the endothelial cells and increased
vascular permeability. Sera from dengue patients were
found to contain apoptosis-inducing factors which might
also play a role in vascular damage [102]. Activation of
the T lymphocytes is the downstream responses of
DENV infection. Considering the diachronic course of
the T cell responses and clinical manifestation of severe
dengue, the cytokine profiles obtained from patients sug-
gested that the key players of the massive release of pro-
inflammatory mediators were the monocytes, macro-
phages and other non-T-lymphocytes. However, T cell
activation might contribute to the cytokine storm in a
subgroup of patients [101].
In light of this, a few studies were devoted to under-
stand the effects of miRNAs on cytokine dysregulation
during dengue infection. Chen et al. (2014) [81] demon-
strated that miR-150 that was highly expressed in DHF
patients was able to negatively regulate SOCS1, a sup-
pressor of cytokine signaling protein whose aberrant ex-
pression could lead to cytokine dysregulation.
Interestingly, they showed a reciprocal correlation
between SOCS1 expression and dengue severity. In light
of the demonstrated association between SOCS1 and
miR-150, it is tempting to speculate that by controlling
the overexpression of miR-150 in dengue patients, the
expression of SOCS1 could be restored and the dysregu-
lation in cytokine expression was rescued [81]. Indeed,
SOCS1 was shown to be involved in immune regulation
during VSV infection [103]. They reported that the sup-
pression of SOCS1 by miR-155 enhanced type I IFN sig-
naling, thereby suppressing viral replication. This
strengthens the notion that by modulating specific miR-
NAs, non-optimal immune responses in patients could
be potentially controlled.
Efforts were also directed to examine the association
between differentially expressed miRNAs and highly ele-
vated cytokines following DENV-2 (strain New Guinea
C) infection [104]. Qi et al. (2013) showed that downreg-
ulation of miR-106b, miR-20a and miR-30b during
DENV-2 infection might relieve inhibition of target
genes, resulting in the increased levels of pro-
inflammatory cytokines. The decrease of miR-106b due
to its downregulation could have led to derepression of
CCL5 and hence increased secretion of this cytokine.
This study offers new insights into possible therapeutic
approaches to attenuate the robust immune response of
the host to DENV infection [104].
Overall, the host miRNAs can act as either proviral or
antiviral via several mechanisms (Table 1). Depending
on the abundance of miRNAs in the host, the impacts of
proviral or antiviral effects can vary. For instance, the
high expression of the proviral miR-146a significantly fa-
cilitated viral replication by targeting TRAF6 and redu-
cing IFN-β production [79]. Dengue severity was
associated with rapid initiation of innate host response
and this innate antiviral mechanism mediated by IFN is
potentially an important pathway of host defense in lim-
iting viral replication. Besides, different miRNAs pro-
duced during DENV infection are associated with the
severity of the disease through cytokine expressions. It
has been suggested that cytokine storm leads to in-
creased plasma leakage seen in DHF and DSS. Several
miRNAs have been reported to be regulating cytokine
production. For example, increased miR-150 was signifi-
cantly associated with DHF concomitant to the suppres-
sion of SOCS1 expression, a negative regulator of several
cytokines [81]. miR-let-7e has been shown to potentially
target the mRNAs of IL-6 and CCL3 while miR-106b,
miR-451, and miR-4279 are targeting mRNAs of CCL5
and CXCL1. Specific differentially expressed miRNAs
appear to cause de-repression of cytokine expressions,
while additional miRNAs target epigenetic modulators
of cytokine expression [104]. However, further studies
should be carried to determine the molecular mecha-
nisms that induce the cytokine storm following DENV
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infection as there is a crucial gap in understanding the
regulation of dengue disease outcomes.
Limitations and delivery of miRNA
Present understanding of the role of miRNAs in the
pathogenesis of dengue is restricted by insufficient
characterization of the miRNA-associated molecular
pathways in dengue infection, replication and host im-
munity [105]. The detection of miRNA targets within a
living organism and in host defense processes with many
layers of molecular and cellular elements remains a
major challenge. One of the challenges in miRNA based
therapies is the off-target effects since a single miRNA
can target multiple mRNAs. Pathophysiological effects
observed by altering their roles might be associated with
changes in the levels of various target mRNAs [105]. De-
livery of miRNAs is one of the key issues that might
limit miRNA mimics and inhibitors being delivered pre-
cisely to the infected and inflamed tissues. This limita-
tion would need to be overcome as it is crucial not to
cause any disturbance to the normal functioning of the
surrounding tissues. Ongoing development of modified
miRNAs and suitable carriers are required to overcome
these problems [106]. However, to date, the delivery of
most miRNA has only been focused on the intended
pathological tissues and organs of interest. The side ef-
fects and toxicities have commonly been overlooked but
this has to be addressed as safety is a critical concern
when investigating a new drug [107].
In addition, miRNA might also activate an innate im-
mune response which is nonspecific and is associated
with the structure, length, chemical modification, cellu-
lar localization and concentration instead of the base se-
quence. Immune activation triggered by miRNAs could
have a negative effect on the health of the recipient.
Thus, a few novel strategies have been developed to re-
duce the miRNA induced immune responses such as
through the use of modified nucleotides (LNAs). Al-
though it has not progressed to clinical trials, in vivo
animal experimentation on the use of LNA-based miR-
146a inhibitor against EV-A71 showed that it could pre-
vent death in mice by restarting the production of type I
IFN. At the early stage of viral infection, prophylactic ad-
ministration of LNA antagomiR-146a was effective. This
demonstrates the potential in vivo application of LNA
for treatment against EV-A71 infection. Since miR-146a
is also present in DENV, in vivo experimentation in the
murine model is much needed to evaluate the thera-
peutic potential of miR-146a.
Conclusion
Molecular understanding of host-virus interaction is es-
sential in the development of more efficient antiviral
strategies. Considering the intrinsic regulatory role of
miRNAs, the hypothesis that miRNAs are playing an im-
portant role in regulating viral pathogenesis has been
the basis of miRNA-related studies on viral infections.
Indeed, this hypothesis has been well supported in den-
gue infection and the roles of miRNAs are discussed in
this review. Understanding and elucidating the roles of
miRNAs in fundamental processes associated with
DENV infection are necessary to fully characterize their
potentials in disease diagnosis and prognosis as well as
disease treatment. The recent study of miRNAs might
provide the tools for identifying common key genes and
pathways that could be activated, repressed or enhanced
in members of Flaviviruses. This would facilitate the
identification of common targets for therapeutic inter-
ventions. Despite the continued efforts of the research
community to seek antiviral agents against dengue infec-
tions, there is currently no effective antiviral treatment
against all four DENV serotypes. As such, miRNAs that
have been shown to affect DENV replication and patho-
genesis do present opportunities as the targets for
miRNA-based antiviral therapeutics for DENV infection.
Nevertheless, the existing miRNA research on DENV re-
mains at the target identification stage. In light of the
advanced stage of development of Miravirsen, an oligo-
nucleotide which has been shown to inhibit the function
of miR-122a in HCV, this miRNA-based therapeutic has
been proven to be a promising strategy to delve into, es-
pecially at a stage where an effective anti-DENV therapy
is still lacking. miR-146a could be taken up as low-
hanging fruit for research in the near future as it is the
only human miRNA induced by different flaviviruses
such as DENV and Japanese encephalitis virus (JEV), as
well as in several other viral infection models including
enterovirus, VSV and hepatitis B virus [108–110]. Mam-
malian cells that were infected with DENV-2, EV-A71,
JEV or VSV produced miR-146a, implying a potential
role of targeting this miRNA in viral infections [79, 94,
109, 111]. Thus, inhibition of miR-146a could reverse
the virus-mediated immune response and by blocking
the miRNA, it could serve as the most straightforward
and easy approach to develop new antivirals. These find-
ings indicate that miR-146a might serve as a promising
therapeutic target for dengue.
To date, there is no in vivo studies in animals or clin-
ical trials being initiated for any of the miRNAs that
have been observed to have antiviral activity against den-
gue infection. Further studies are needed to verify
whether the miRNAs known to have antiviral effects
against DENV serotypes in vitro will exhibit anti-DENV
effects in vivo and whether they are able to protect mice
from lethal challenges with DENV serotypes 1–4. With-
out known targets in vivo in an animal model, the devel-
opment of miRNAs as promising targets of intervention
against dengue is still exploratory. Moreover, research
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should focus on special delivery systems that target spe-
cific tissues to reduce therapeutic doses and unwanted
side effects. The selection of the lead miRNA to develop
into an antiviral therapeutic will have to depend on both
in vitro and in vivo performance in animal models.
Thus, efficient in vivo delivery is critical for their suc-
cessful use in an animal model. The use of nanocarriers
and new non-invasive imaging techniques should be de-
veloped to monitor the in vivo distributions of the thera-
peutic nanocarriers that might help to optimize the
treatment efficacy. The miRNAs have to maintain high
stability in tissues by having good pharmacological prop-
erties and displaying no toxicity at the concentrations
being administered. Besides these desirable attributes,
the miRNA should not display off-target effects. On-
going development of modified miRNAs and suitable
nanocarriers are required to overcome these problems.
The development of non-viral systems for the delivery of
miRNA has undergone extensive expansion in recent
years, providing solutions for the challenges hampering
miRNA therapeutic success. The most advanced ap-
proach for systemic delivery was via lipid nanoparticles
as a carrier system which is currently ongoing in Phase
I-III human clinical trials. Nevertheless, the delivery of
miRNA to organs other than the liver has been challen-
ging and the toxicity of the nanocarriers is of concern.
Thus, preclinical evaluations of miRNA administration
using animal models is necessary to determine the effi-
ciency of miRNA delivery to other organs besides the
liver, as well as examining the potential safety.
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